Pulmonary disease caused by Mycobacterium avium complex (MAC) is increasing. Treatment plans include multidrug therapy that can last for up to 2 years, which causes negative side effects or drug-resistant strains. Trans-translation is a ribosome rescue pathway that rectifies nonstop translation to make ribosomes available for translation. To determine the effectiveness of trans-translation inhibitors against MAC, MIC and MBC assays were performed. Trans-translation inhibitors exhibit great promise for drug development and future use against MAC.